How Do You Localize Labels and Instructions for Use for Medical Device Registration in Malaysia?

To localize the label and instructions for use (IFU) for a medical device registered with Malaysia's Medical Device Authority (MDA), you must first confirm the device classification and the applicable submission pathway, then rework the existing label and IFU content — language, mandatory content elements, intended-use statements, warnings, storage and transport conditions, UDI or traceability information, importer details, authorized representative details and after-sales contact information — so that it is fully consistent with the technical file, test reports, risk management documents, clinical evidence and quality management system certificate you intend to submit. Localization is not a translation exercise; it is a consistency exercise across the entire evidence chain, and it should be planned together with the appointment of a local representative and the control of the registration certificate, not after the submission.

Published: 10 July 2026 | Updated: 10 July 2026

This article addresses the questions companies most often need to resolve first when planning international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Key Takeaways

• Documentation for MDA medical device registration is normally prepared around product classification, technical documentation, ISO 13485 quality system evidence, performance verification, risk management, clinical evaluation or clinical evidence, labels and IFUs, authorization documents and local representative arrangements.
• Companies should complete a documentation gap assessment before deciding whether existing NMPA, CE, FDA or other market files can be reused.
• Registration in a target market typically affects the technical file, authorized representative arrangements, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time.
• If a project is driven only by the question of which documents to submit, corrections and rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control.
• AIMEILI recommends planning this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than rebuilding documents country by country.

Prepared from the AIMEILI regulatory practice database, the AIMEILI medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the underlying product documentation.

When This Applies and the Core Question

Companies searching for how to localize labels and IFUs for medical device registration in Malaysia are usually not looking for a conceptual explanation. They want to know whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines become extended, and which issues will affect the launch plan. Behind this question there are typically several connected topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the procedure for one country alone is not sufficient. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels and IFUs, and then adapt them to each country's regulatory requirements.

How to Decide the Registration Pathway

Companies should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, sterility status, whether the device is active, and whether it contains software or has IVD characteristics. Only then can the risk class and submission pathway be determined. If the pathway is wrong from the outset, all subsequent translation, notarization, authorization, testing and supplementary documentation will follow the wrong direction.

For a target market project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are only handled vaguely in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical documentation, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labels and IFUs, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended purpose, not on how many documents have been uploaded.

Common Mistakes

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating domestic NMPA documentation and submitting it directly, without restructuring the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not provide adequate coverage.
• Selecting a local agent purely on the basis of a sales relationship, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, IFUs, promotional materials and registration claims, resulting in deficiency letters or post-market compliance risk.
• Failing to plan multi-country document reuse in advance, so that each country requires a separate effort and both cost and timelines are multiplied.

Company Preparation Checklist

Before launching a project, companies should use an internal checklist to confirm the documentation baseline, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Build a target-country gap assessment table that identifies what must be re-tested, translated, notarized or supplemented with declarations.

The AIMEILI Perspective

AIMEILI advises companies not to view target market registration as a one-off document submission, but to manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable and more conducive to subsequent changes and renewals than supplementing documentation market by market.

From a project management perspective, three things should be controlled as early as possible: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, a project may still encounter repeated cycles during deficiency responses, agent communication and post-market maintenance, no matter how extensive the documentation appears.

Frequently Asked Questions

Can domestic documentation be used directly for registration in the target market?

Domestic documentation can serve as a foundation, but it normally cannot be submitted as-is. Companies need to adjust the documentation structure, language, labels, authorization documents and evidence chain in line with local regulatory requirements. In the case of Malaysia, the label and IFU content must also satisfy the MDA's mandatory content and language requirements, and the information must match the technical file and test reports actually submitted.

When is the best time to start a gap assessment?

A gap assessment should be started immediately after the target market and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to schedule additional testing, translation, label adjustments and agent selection in advance. Delaying the assessment until the submission package is being assembled is one of the main causes of extended timelines.

Why does the choice of local agent affect registration quality?

The local agent is typically involved in registration communication, changes, renewals and post-market event handling. If rights and responsibilities are unclear, certificate control and subsequent market stability can be affected. Companies should therefore define the agent's regulatory duties, document ownership, communication obligations and exit arrangements before appointing it, rather than relying on general commercial terms.

Project Execution Recommendations

When executing this type of registration project, companies should maintain a project tracker that consolidates the product list, model and specification matrix, registration pathway, document owners, translation status, testing status, local agent communication records and estimated submission dates in a single table. This makes documentation gaps visible in good time and allows management to judge whether the project will affect the launch plan.

For companies that already hold registrations in several countries, an evidence reuse matrix should also be established, clarifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labels and IFUs, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Assign post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical documentation are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the device being registered, or if the manufacturing site, model and specification matrix or IFU version conflicts with the test reports, the company may be asked for supplementary explanations even if a large volume of documentation has been prepared.

Before submission, companies should build an evidence consistency checklist mapping product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate. This step appears basic, but it can significantly reduce the probability of deficiency letters, particularly for projects involving multiple GHWP member states or several product families submitted at the same time.

Localization Conversion and Representative Responsibilities

Target market registration projects usually involve a local agent, authorized representative, importer or registration holder arrangement. Companies need to confirm in advance whether the local partner is only responsible for submitting documentation, or whether it also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to translate reusable evidence into a submission structure acceptable in the target country, not to write a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort at the registration stage but neglect post-market maintenance, so that when a manufacturing site change, model extension, IFU update or agent replacement occurs, the certificate and the marketed product become disconnected.

AIMEILI recommends managing this question within an annual international registration plan: first establish target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency for a single country registration; more importantly, it enables companies to build a replicable compliance capability for overseas expansion and to reduce the cost of starting from zero each time they enter a new market.

Further Reading

• How should technical documentation for medical device registration in Malaysia be organized?
• How should clinical evaluation documentation for medical device registration in Malaysia be prepared?
• How should registration documentation for medical device registration in Malaysia be prepared?
• How is product classification determined for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?
• How should an ISO 13485 certificate be used for medical device registration in Malaysia?

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions or legal advice.